• Contact
  • EPAD Academy
Top Bar Menu
TwitterFacebookYouTube
Search...
EPADEPAD
EPAD
European Prevention of Alzheimer's Dementia Consortium
  • Home
  • About
    • Welcome to EPAD
    • Project Objectives
    • Project Structure
    • EPAD Partners
    • Coordination & Management
    • EPAD Q&A
  • Our research
    • Participation in EPAD
      • Participation in EPAD Cohort
      • EPAD Study Visits
      • Trial Locations
      • Participation FAQs
    • The Participant’s Experience
      • The Research Participant Panel
      • EPAD Stories
    • The EPAD platform
      • The EPAD Platform
      • EPAD Benefits
      • Clinical Candidate Selection
      • EPAD FAQs
      • Research Resources
  • Open Access Data
    • Overview
    • Access
    • Data
    • Samples
    • MRI Images
  • News & Publications
    • Latest News
    • Newsletters
    • Publications
    • Videos
Menu back  

Interview with Rodrigo Barnes

2020-04-30News

Tell us a bit about the institution/company/organisations you work for.

For the last twelve years, I’ve been working at Aridhia (https://aridhia.com), an SME based in Edinburgh and Glasgow specialising in informatics for biomedical research. After working for some years with specialist clinicians in hospitals and clinics with specialised medical data, we found our current focus at the intersection of clinics, universities and the pharmaceutical industry. As the permaculture people say, ‘cultivate the edge’ – it turns out that’s where the interesting things happen. Our Digital Research Environment (DRE) is a service for securely sharing patient and participant data and running state of the art statistics and machine learning in the cloud. Our job is to make it convenient and secure for communities like EPAD and their wider ecosystem.

What is your current role in EPAD?

My background is in mathematics (not statistics!) so far my career has been in the software industry, designing information intensive systems – most recently in the scientific domain. As part of Work Package 4 from the start, my role was driving to design the ‘information architecture’. At the time we knew that a project like EPAD LCS would need both the regulatory database (GCP) and an as-yet-undefined analytical database (GXP for Analytics? that could evolve as the scientific and operational needs were better understood. As well as defining processes for bringing data in and making it useful for multiple purposes, we adapted a data model I had developed integrating hospital data.

More recently, I have been involved in what comes after the IMI EPAD, from various angles, business and informatics. I am excited at the possibility of taking our expertise in international collaboration to the next level.

How Aridhia is contributing to facilitate and generate EPAD data release?

We have learned so much from working in EPAD, and one of the most interesting aspects has been to help define a robust data sharing process for the LCS data. Our team worked with the sponsors, industry partners and l’Academie to achieve this and are involved at every stage. Our data team generate the published snapshots of the analytical database, and publish snapshots and metadata. Researchers can discover the data through publications, Internet searches and go through a partially automated process to request access. A semi-automated process streamlines the review and approval of requests. Data is then usually delivered to a private Workspace in the DRE where they can download the open data, collaborate on analysis and also redeposit derived data back to the LCS. Experience of this process is feeding back into our product design so that we can improve the potential for data discovery and reproducibility in science.

What value do you see in public-private collaboration and networking with related initiatives?

We took a strategic decision to invest in EPAD – at the time we had little experience of working directly with industry and our offer was not well understood in this domain. The IMI programme created the conditions for us to learn from the EPAD network and has had a very positive impact in developing our business. On a personal level, it has been a rewarding community of colleagues to work with. Three critical factors were the public-private funding, the scale of being European-wide and the pre-competitive agreements on intellectual property. This combination got us started working with the EPAD partners and setup a framework for us to make a wider contribution than we could have otherwise.

What are the most prominent challenges you see in Alzheimer’s disease research?

What I say here is not as a scientist or clinician. As a lay person, I can see the absence of disease modifying therapies leaving patients with little hope, and the challenge of making sense of brain health or disease progression over many years. My specialised perspective sees the patchy and evolving data that hampers clinical and scientific solutions, and the difficulties of distributing analytics-based tools to where they are needed. For now, the Aridhia team and I are working on two specific aspects – how to maximise the available data or design more compatible datasets through international collaborations, and how to deliver machine learning and other decision support into the clinic at scale.

 

Share this post
FacebookTwitterLinkedInGoogle+
Related posts
Closing EPAD article published in the Alzheimer Europe magazine
2021-02-24
Alzheimer Europe launches a report on data sharing in dementia research
2021-02-23
Local actions to keep the EPAD Longitudinal Cohort data collection going
2021-02-17
Neuronet releases its Knowledge Base dashboard
2021-02-01
The final EPAD dataset is now available to the entire research community
2020-11-30
ALZFORUM
Alzforum conference blog mentions EPAD
2020-11-30
Latest News
  • Closing EPAD article published in the Alzheimer Europe magazine
    2021-02-24
  • Alzheimer Europe launches a report on data sharing in dementia research
    2021-02-23
  • Local actions to keep the EPAD Longitudinal Cohort data collection going
    2021-02-17
  • Neuronet releases its Knowledge Base dashboard
    2021-02-01
  • The final EPAD dataset is now available to the entire research community
    2020-11-30
View the EPAD Brochure
thumbnail of EPAD brochure
Speak to the EPAD team
thumbnail of speech bubbles
Twitter
Twitter
EPAD
EPAD
@IMI_EPAD

.@AlzheimerEurope has published a new edition of its “Dementia in Europe” magazine. It includes a closing article on @IMI_EPAD. Our co-leads @craig_ritchie68 and Serge Van der Geyten, reflect on the achievements of the project. Download the PDF here: bit.ly/DementiaInEuro… twitter.com/AlzheimerEurop…

reply retweet favorite
12:40 pm · 2021-02-24
Twitter
EPAD
EPAD
@IMI_EPAD

Last week, we held the first local @IMI_EPAD community meeting among the Scottish research sites, collaborators, academics & scientists who have been involved in our Longitudinal Cohort Study and now continue to contribute to the study locally More info⤵️ ep-ad.org/2021/02/17/loc… pic.twitter.com/MTKmanCURk

reply retweet favorite
6:51 am · 2021-02-24
Twitter
EPAD
EPAD
@IMI_EPAD

Check out the new @AlzheimerEurope report on #DataSharing in #dementia #research, which reviews recent changes in EU research policy and sets out recommendations to improve data sharing. It includes case studies from ADNI, @IMI_EPAD and @IMI_EMIF. ⬇️ Bit.ly/DataSharing_AE twitter.com/AlzheimerEurop…

reply retweet favorite
2:39 pm · 2021-02-23
Twitter
EPAD
EPAD
@IMI_EPAD

Scottish @IMI_EPAD members have been invited to join the first #EPADcommunity meeting. Today, we're discussing about publications, #data access, communications, participant panel, #network & #collaborations. Nice to see some #epadistas sharing their insights 👨‍⚕️👩‍🔬👩‍💻 pic.twitter.com/O1hLAVxk0Q

reply retweet favorite
2:23 pm · 2021-02-17
Twitter
EPAD
EPAD
@IMI_EPAD

The new issue of the @IMI2_NEURONET #newsletter is out with latest news on @IMI_EPAD, @IMI_AMYPAD, @RADARCNS among others. Find out more here: bit.ly/Neuronet-Newsl… twitter.com/IMI2_NEURONET/…

reply retweet favorite
2:12 pm · 2021-02-15
Copyright © 2015-19 EPAD | Created by CMAST and Aridhia
  • Acronyms
  • Legal Notice
  • Privacy Policy
Bottom Menu

efpia-logo EU imi logo

This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement nº 115736

This website uses cookies to improve your experience. Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.